乌司奴单抗治疗克罗恩病的真实世界长期有效性:ENEIDA登记研究结果
多中心研究纳入407例以推荐剂量起始乌司奴单抗的难治性克罗恩病患者并随访1年。52周时27.5%患者停药,基线HBI>4分的患者中57%和64%分别在26周和52周达到临床缓解,粪钙卫蛋白正常化率44%和54%,CRP正常化率36%和37%。
要点
- 基线HBI>4分的295例患者中,26周和52周临床缓解率分别为57%和64%。
- 52周时粪钙卫蛋白正常化率54%,CRP正常化率37%。
- 既往抗TNFα药物使用较少和回肠定位与临床缓解相关,内镜严重程度与应答不佳相关。
核心结论
- 乌司奴单抗在难治性克罗恩病患者中于52周时显示出诱导临床缓解和内镜缓解的有效性。
研究设计与样本
- 多中心研究,纳入以推荐剂量起始乌司奴单抗的克罗恩病患者407例,随访1年。
主要发现
- 初始维持剂量90 mg皮下注射每12周、每8周和每4周给药者分别为56例(14%)、347例(85%)和4例(1%)。
- 52周后112例患者(27.5%)停止治疗。
- 基线HBI>4分者295例(72%),其中26周和52周达到临床缓解者分别为169例(57%)和190例(64%)。
- 粪钙卫蛋白在26周和52周恢复正常者分别为44%和54%,CRP在26周和52周恢复正常者分别为36%和37%。
- 60例患者记录到不良事件。
关键数值与推荐
- 既往抗TNFα药物使用较少和回肠定位与临床缓解相关,内镜严重程度与应答不佳相关。
- 未发现与内镜缓解相关的因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on the long-term administration of ustekinumab in recommended doses are limited. AIM: To assess the real-world, long-term effectiveness of ustekinumab in refractory Crohn's disease (CD). METHODS: Multi-centre study of CD patients starting ustekinumab at the recommended dose, followed for 1 year. Values for the Harvey-Bradshaw Index (HBI), endoscopic activity, C-reactive protein (CRP), and faecal calprotectin (FC) were recorded at baseline and at weeks 26 and 52. Demographic and clinical data, previous treatments, adverse events (AEs) and hospitalisations were documented. Potential predictors of remission were examined. RESULTS: A total of 407 patients were analysed. The initial maintenance dose of 90 mg SC was administered every 12, 8 and 4 weeks in 56 (14%), 347 (85%) and 4 (1%) patients, respectively. After 52 weeks, treatment was discontinued in 112 patients (27.5%). At baseline, 295 (72%) had an HBI >4 points. Of these, 169 (57%) and 190 (64%) achieved clinical remission at weeks 26 and 52, respectively. FC levels returned to normal in 44% and 54% of patients at weeks 26 and 52, and CRP returned to normal in 36% and 37% of patients at weeks 26 and 52, respectively. AEs were recorded in 60 patients. The use of fewer previous anti-TNFα agents and ileal localisation were associated with clinical remission, and endoscopic severity was associated with poor response. No factors correlated with endoscopic remission. CONCLUSION: After 52 weeks, ustekinumab demonstrated effectiveness in inducing clinical and endoscopic remission in patients with refractory CD.
引用
- Iborra M, Beltrán B, Fernández-Clotet A, et al. Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2020. PMID: 32770851. doi:10.1111/apt.15958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。